LRAD, MLNK, PFE - CRWESelect.com Stock News! LRAD Corporation, ModusLink Global Solutions, Pfizer (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) December 5, 2011 -- To view video, and read the full article visit URL http://crweselect.com/27647/stock-alerts/lrad-mlnk-pfe-crweselectcom-stock-news-lrad-corporation-moduslink-global-solutions-pfizer-video-included-inside/

LRAD Corporation (NASDAQ:LRAD)

LRAD reported today record revenues of $26.5 million and record net income of $0.15 per diluted share for the fiscal year ended September 30, 2011. The Company achieved record revenues for the fourth straight fiscal year and second consecutive year of profitability; the first two years of profitability in the Company's history. Also, the Company recorded fifth consecutive fiscal year of double digit LRAD® systems and services sales growth.

LRAD has thousands of Long Range Acoustic Device® (LRAD®) communication systems in service around the world in diverse applications including fixed and mobile military deployments, maritime security, critical infrastructure and perimeter security, commercial security, border and port security, law enforcement and emergency responder communications, asset protection and wildlife preservation and control.

For more information about LRAD please visit http://www.lradx.com

****

ModusLink Global Solutions, Inc. (NASDAQ:MLNK)

MLNK reported today financial results for its first quarter of fiscal year 2012 ended October 31, 2011. The Company experienced net revenue of $206.2 million, compared to $236.4 million in the first quarter of fiscal 2011. Also, they experienced gross margin as a percentage of revenue of 12.6%, compared to 9.5% in the first quarter of fiscal 2011. The Company net income for the first quarter of 2012 was $1.6 million, or $0.04 per share, compared to net loss of $6.7 million, or ($0.15) per share, for the same period in fiscal 2011.

MLNK designs and executes global value chain strategies to solve clients’ cost, time-to-market, customer satisfaction and revenue objectives. Their supply chain, aftermarket, e-Business and entitlement management solutions support the end-to-end product lifecycles of the world’s leading technology and consumer goods companies. ModusLink has more than 25 years of experience executing complex supply chain processes such as sourcing, configuration and fulfillment. They can manage these critical functions seamlessly with a client’s global e-Business initiative or an integrated aftermarket program, including alternative channel recovery for at-risk inventory. Backed by a footprint of more than 25 solution centers in 15 countries, ModusLink clients can react quickly to shifting market dynamics impacting value chain performance and revenues.

For more information about MLNK please visit http://www.moduslink.com/

****

Pfizer, Inc. (NYSE:PFE)

PFE announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 – Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. The study met its primary endpoint: treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urgency urinary incontinence (UUI) episodes per day at the end of treatment. Further analyses will be conducted and a publication of the comprehensive results is planned at a later date.

PFE apply science and their global resources to improve health and well-being at every stage of life. They strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Their diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products.

For more information about PFE please visit http://www.pfizer.com

To read the full article visit URL http://crweselect.com/27647/stock-alerts/lrad-mlnk-pfe-crweselectcom-stock-news-lrad-corporation-moduslink-global-solutions-pfizer-video-included-inside/

*****************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

LRADcrweselect1205
MLNKcrweselect1205
PFEcrweselect1205

LRAD     LRAD Corporation     MLNK     ModusLink Global Solutions     PFE     Pfizer     Toviaz